DxScript vs EPrescribeMD Utilisation & Stats

DxScript® ePrescribing service puts eligibility, benefits, and formulary information at your fingertips at the time of prescribing. This enable prescriber to select medications that are on formulary and are covered by the patient's drug benefit. It also informs you of lower cost alternatives such as generic drugs. Prescriber can access a timely and clinically sound view of a patient's prescription history across providers, at the point of care. This decreases the risk of preventable medication errors. DxScript® replaces old, error-phone approach to writing. Printing new prescription electronically in your office reduces the risk of medication errors associated with poor handwriting, illegible faxes and manual data entry. Using DxScript® to process prescription renewals saves you time and money by dramatically reducing the number  of phone calls and faxes typically associated with the prescription renewal authorization process.
  • Apple App Store
  • Gratuit
  • Médical

Classement dans le store

- -

The ePrescribeMD is the latest app to be launched by HospiceMD Inc. The app is primarily for doctors. They can now review and e-prescribe medications as well as approve agencies via the App. The App is solely meant as a tool to send out e-prescriptions and needs to be used in tandem with the HospiceMD website. Therefore, e-prescriptions and agency request are only populated if they are entered via the site.
  • Apple App Store
  • Gratuit
  • Santé & Fitness

Classement dans le store

- -

Comparaison des classements DxScript vs. EPrescribeMD

Comparez l'évolution du classement de DxScript au cours des 28 derniers jours à celle de EPrescribeMD.

Rank

Aucune donnée disponible

Comparaison des classements DxScript et EPrescribeMD par pays

Comparez l'évolution du classement de DxScript au cours des 28 derniers jours à celle de EPrescribeMD.

Aucune donnée à afficher

Comparez avec n'importe quel site grâce à notre essai gratuit

Démarrer
DxScript VS.
EPrescribeMD

14écembre d, 2024